The vice president of Sinopharm China Biologics has said that virus mutations will always exist and that humans cannot stop them. Small mutations of the virus do not affect the antigenicity of the vaccine, meaning that without mutations that produce protective antigens, the vaccine will be effective, especially for whole virus inactivated vaccines. Sinopharm China has rich experience in vaccine development, and even in the case of large mutations of the new coronavirus, it can respond quickly and effectively under the guidance of the National Vaccine Task Force, the Drug Administration and other relevant departments for rapid processing, and the development of vaccines for the relevant mutated strains is currently being actively promoted. Moreover, this year, WHO issued an emergency use certification for the New Crown vaccine of China National Pharmaceutical Group Co. Sinopharm China’s inactivated New Crown vaccine has been used in 50 countries and regions around the world, and the wide range of population samples and regions fully demonstrates that the inactivated New Crown vaccine has a broad-spectrum effect. As of March this year, 9 months of antibody test data have been obtained from the population who received inactivated New Crown vaccine in March last year, and the data shows that the antibody is still at a certain level at 9 months. At the same time, KeXing Zhongwei has cooperated with several research institutions to carry out research on the protective effect of New Crown vaccine kerafol on each country’s variant strains. In the early stage of the research, neutralization tests have been conducted on the variant of virus strains from 10 countries, which also proved that the vaccine developed at that time was protective against each country’s variant strains. In this year, WHO also issued emergency use certification for KeXing Zhongwei vaccine. Moreover, the Phase III clinical trials of the new crown vaccine are being conducted simultaneously in Brazil in South America, Indonesia in Southeast Asia, and Turkey in the Middle East, three countries with different geographical characteristics and different variant prevalent strains, forming a global clinical research layout. The Wuhan strain and the UK strain have achieved 100% positive seroconversion and the South African strain has achieved 97% positive seroconversion. However, so far, the protection rate of the new crown vaccine is not 100%, no matter the protection efficacy obtained in clinical trials or the protection effect obtained after the vaccine is released, and it takes some time to produce protective antibodies. Some people have also developed infections after vaccination, but this does not mean that the vaccine is not effective enough. The best way to prevent Neoplastic pneumonia is to get vaccinated, and by getting vaccinated and achieving herd immunity, we can reduce the intensity of Neoplastic pneumonia or stop its prevalence.